secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2021-08-18T23:59:59+00:00
Accession:  0001493152-21-020512
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K
--------------------------------------------------------------------------

- Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.
- Loan bears 8% interest, due in 12 months; convertible into Series D-1 Preferred at $2.862/share (each converts to 10 common shares).
- On Aug 16, 2021, CFO Heather Raines invested $200,000 via a 2021 Note under the same terms.
- Proceeds to fund drug discovery/development and general administrative expenses.
- Issuance exempt from registration under Section 4(a)(2) or Rule 506 of the Securities Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/0001493152-21-020512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-020512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer